Antiplatelet therapy not effective in treating critically ill COVID-19 patients: REMAP-CAP

Antiplatelet therapy with either aspirin and P2Y12 inhibition was ineffective at improving death and organ support free days in critically ill COVID-19 patients, latest results from REMAP-CAP show. The findings are based on an analysis of 1467 critically ill patients and are yet to be peer reviewed and published. Previously, aspirin and P2Y12 inhibition had ...

Already a member?

Login to keep reading.

© 2021 the limbic